The FINANCIAL -- NYSE Euronext announced the
listing on NYSE Alternext in Paris of Theradiag, specialising in in
vitro diagnostics and theranostics.
Theradiag sells new-generation blood tests used in diagnostics and pronostics to monitor patient response and allow clinicians to anticipate, optimise and better manage treatments. As NYSE Euronext announced, the company has unique expertise and innovative capacity in the distribution and development of in vitro diagnostic products that have won recognition in their respective markets. Backed by sales of around €10 million in 2011 and €4.6 million at 30 June 2012 in in vitro diagnostics, Theradiag is developing two innovative lines of theranostic products: Lisa-Tracker kits for patients suffering from autoimmune diseases and the microARN platform for predicting effectiveness and monitoring AIDS therapies.
Theradiag was listed through admission to trading of 2,345,320 existing shares and 1,410,377 new shares issuedunder a Global Offering. The Global Offering raised a total of €8.1 million.
The admission and issue price of Theradiag was set at €5.80 per share, near the high end of the indicative spread. Market capitalisation stood at around €21.7 million on the day of listing.
“We are delighted to welcome Theradiag to NYSE Alternext. This listing, which has been a real success, will enable the company to continue developing innovative solutions while generating the resources it needs to fully adapt to conditions in its constantly evolving sector,” said Marc Lefèvre, Head of European Business Development and Client Coverage, Listings Europe, NYSE Euronext. “Biotech and medtech businesses are terrific drivers of competitiveness. They create jobs and play an active role in growing our economy. It is our responsibility to deliver the support they need.”
Michel Finance, CEO of Theradiag, added “We would like to thank all of our employees and partners, in particular our majority shareholder Truffle Capital, along with our new shareholders for their confidence and support. Funds raised represent additional resources that we will harness to finance our future growth in theranostics and new therapies for inflammatory and autoimmune diseases, cancer and AIDs, rounding out our existing Lisa-Tracker line and microARN platform. Naturally we will also be adding to our lines of innovative proprietary diagnostics products and their sale on international markets.”
In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalisation totals €6 billion. Today 178 companies are listed on NYSE Alternext.
Related Stories
